Species D adenoviruses as oncolytics against B-cell cancers

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6712-6722

  Chen, Christopher Y ^a   Senac, Julien S ^a   Weaver, Eric A ^a   May, Shannon M ^a   Jelinek, Diane F ^a   Greipp, Philip ^a   Witzig, Thomas ^a   Barry, Michael A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC ADENOVIRUS; SIALIC ACID; SYNDECAN 1;

ADENOVIRUS; ADENOVIRUS 11; ADENOVIRUS 17; ADENOVIRUS 24; ADENOVIRUS 26; ADENOVIRUS 28; ADENOVIRUS 30; ADENOVIRUS 35; ADENOVIRUS 4; ADENOVIRUS 45; ADENOVIRUS 48; ADENOVIRUS 5; ADENOVIRUS 6; ADENOVIRUS 7; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; LYMPHOMA CELL; MARGINAL ZONE LYMPHOMA; MOUSE; MYELOMA CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RECEPTOR BINDING; STRAIN DIFFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MICE; MICE, NUDE; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052992089     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0968     Document Type: Article

References (34)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2008. Based on November 2010 SEER data submission. Bethesda (MD): National Cancer Institute; 2011. Available from: http://seer.cancer.gov/csr/1975-2008/ 〈https://imail.mayo.edu/csr/1975- 2008/〉.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
3. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6:529-40. (Pubitemid 351850977)
4. Barry MA, Hofherr SE, Chen CY, Senac JS, Hillestad ML, Shashkova EV. Systemic delivery of therapeutic viruses. Curr Opin Mol Ther 2009;11:411-20.
5. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000;74:2567-83. (Pubitemid 30117566)
6. Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther 2001;8:930-7. (Pubitemid 32600149)
7. Lichtenstein DL, Wold WS. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 2004;11:819-29. (Pubitemid 39636349)
8. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 2010;21:179-90.
9. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999;23:127-36. (Pubitemid 29067556)
10. Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 2006;46:2083-9. (Pubitemid 44813725)
11. Garnett CT, Talekar G, Mahr JA, Huang W, Zhang Y, Ornelles DA, et al. Latent species C adenoviruses in human tonsil tissues. J Virol 2009;83:2417-28.
12. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 1990;82:501-9. (Pubitemid 20108054)
13. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966;37:547-59.
14. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins avb3 or avb5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-19.
15. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3. (Pubitemid 27114163)
16. Segerman A, Lindman K, Mei YF, Allard A, Wadell G. Adenovirus types 11p and 35 attach to and infect primary lymphocytes and monocytes, but hexon expression in T-cells requires prior activation. Virology 2006;349:96-111.
17. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9:1408-12. (Pubitemid 37466191)
18. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006;80:12109-20. (Pubitemid 44904362)
19. Arnberg N, Kidd AH, Edlund K, Olfat F, Wadell G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J Virol 2000;74:7691-3. (Pubitemid 30613120)
20. Arnberg N, Edlund K, Kidd AH, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000;74:42-8. (Pubitemid 30002881)
21. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009;19:165-78.
22. Burmeister WP, Guilligay D, Cusack S, Wadell G, Arnberg N. Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol 2004;78:7727-36. (Pubitemid 38915919)
23. Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, Hippert C, et al. The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog 2009;5:e1000277.
24. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007;81:4654-63. (Pubitemid 46668663)
25. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993;268:20205-10. (Pubitemid 23278923)
26. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300.
27. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998;101:1013-9. (Pubitemid 28248886)
28. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003;7:163-73. (Pubitemid 36395351)
29. Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J Invest Dermatol 2008;128:988-98. (Pubitemid 351374310)
30. Hoffmann D, Heim A, Nettelbeck DM, Steinstraesser L, Wildner O. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. HumGene Ther 2007;18:51-62. (Pubitemid 46105464)
31. Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res 2009;69:5115-25.
32. Shashkova EV, May SM, Barry MA. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 2009;394:311-20.
33. Chen CY, Weaver EA, Khare R, May SM, Barry MA. Mining the adenovirus virome for effective oncolytics against solid tumors. Cancer Gene Therapy 2011. Epub ahead of print.
34. Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 2008;22:361-9. (Pubitemid 351250541)